Genomics-guided personalized disease prevention, target-tailored precision medicine (http://genlighttechnology.com). Personalized genomics-guided precision medicine for therapy-resistant prostate and breast cancers (http://genlighttechnology.com). Inflammation & autoimmune disorders. Prostate, breast, and colon cancer risk assessment, diagnostic, prognostic, and therapy-selection services (http://
genlighttechnology.com). Genlighttechnology provides unique, proprietary approach to consulting, diagnostics, and therapy-selection disease management and health maintenance services for individuals diagnosed with prostate & breast cancers. We provide these services to assist practicing physicians and cancer patients in decision-making process at the time of diagnosis of tumors in the prostate when the critical decision is made to select active surveillance ("watchful waiting") or aggressive therapeutic interventions with curative intent such as radical prostatectomy. Here is how it works.
1. You are diagnosed with prostate cancer. We will help to make a choice what treatment options to select. For many patients, it may be possible to determine before the treatment how likely is that initial therapy may fail and how soon cancer may come back after the treatment. This information will help to make a decision whether the individual patients are more or less likely to benefit from immediate or near-term therapeutic interventions. This is important because:
i) Treatment of prostate cancer is often associated with complications which significantly affect the quality of life of patients. These complications will adversely affect patients’ life to a greater extent than disease itself. ii) Most patients diagnosed with the early-stage prostate cancer will have clinically indolent disease. They typically have no clinical symptoms and disease will have no adverse effects of their well-being and quality of life. Therefore, these patients do not need immediate aggressive treatment because there will be no significant survival benefits from the treatment during their lifetime.
2. You already received treatment for prostate cancer. Your disease is in remission or you are “cancer-free”. For many patients, after the initial therapy was administered and they are "cancer-free'” with no clinical evidence of disease, we may be able help to determine the likelihood of therapy failure and disease relapse in the future. We may be able to determine how likely is that cancer may come back because patients have clinically latent residual disease and how soon it may progress to clinically lethal metastatic cancer. This is important because as early detection of primary tumors helps to increase the likelihood of cure, early detection of clinically latent residual disease may help to prevent the disease progression to metastatic, late-stage, lethal disease with no significant prospect of cure or choices of effective treatment options. We hope that this knowledge will help you, your family, and your doctors to make rational, evidence-based decisions on what steps to take and how to manage your life after being diagnosed with cancer.
